Vir Biotechnology, Inc. (NASDAQ:VIR) presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback